Document Detail


Large-scale production means for the manufacturing of lentiviral vectors.
MedLine Citation:
PMID:  21054245     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
Lentiviral vectors become more and more famous for the use as gene vector for gene therapy purposes for the treatment of acquired or inherited diseases. In this review, the present state of the art of the production of lentiviral vectors is presented with particular emphasis on the large scale production of these vectors for preclinical and clinical purposes. In contrast to oncoretroviral vectors which are produced using stable producer cell lines, clinical grade lentiviral vectors are essentially produced by transient transfection of 293 or 293T cells grown in Cell Factories. The main reason is that these production processes have been developed when good and safe LV producer cell lines were not available. With respect to the purification of lentiviral and in agreement with actual developments in the biotech industry, rather sophisticated downstream processing protocols have been established in order to remove any potentially dangerous process derived contaminant, such as plasmid or host cell DNA or host cell proteins. This review presents large scale production means for LV vectors, the different downstream processing steps as used for the purification of LV vectors as well as LV specific safety issues. Published large scale production and purification processes of lentiviral vectors and their process performances are compared.
Authors:
M Schweizer; O-W Merten
Related Documents :
8579725 - Cytoplasmic accumulation of the 52 kda ro/ss-a nuclear autoantigen in transfected cell ...
11642555 - Monitoring transfected cells without selection agents by using the dual-cassette expres...
9094435 - Modulation of cell surface lectin receptors on k562 human erythroleukemia cells induced...
15476585 - Cell-cell interaction mediated by cadherin-11 directly regulates the differentiation of...
24714215 - The 19s deubiquitinase inhibitor b-ap15 is enriched in cells and elicits rapid commitme...
12377585 - Don't bother to knock--the cell invasion strategy of trypanosoma cruzi.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current gene therapy     Volume:  10     ISSN:  1875-5631     ISO Abbreviation:  Curr Gene Ther     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-12-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101125446     Medline TA:  Curr Gene Ther     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  474-86     Citation Subset:  IM    
Affiliation:
Paul-Ehrlich-Institut, Division of Medical Biotechnology, Paul-Ehrlich-Str. 51-59, D-63225 Langen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Production of non viral DNA vectors.
Next Document:  Production of retroviral vectors: review.